University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > Treatment > Charts & Tables
Antiretroviral Management Charts and Tables
gray line
transparent gif
Special Situations
transparent gifgrey bulletDosing of Antiretroviral Drugs in Adults with Chronic Kidney Disease and Hemodialysis
Ian R. McNicholl, PharmD, BCPS, and Rudolph A. Rodriguez, MD, University of California San Francisco. Updated October 2012.
transparent gif
transparent gifgrey bulletDosing for Ritonavir-Boosted Protease Inhibitors
Susa Coffey, MD, and Ian R. McNicholl, PharmD, BCPS, University of California San Francisco. Updated July 2010.
transparent gif
Adverse Effects
transparent gifgrey bulletAdverse Effects of Antiretroviral Drugs
Ian McNicholl, PharmD, BCPS, University of California San Francisco. Updated October 2012.
transparent gif
transparent gifgrey bulletAdverse Events Due to Nonantiretroviral Medications during Treatment of HIV-Related Infections and Complications
Ian McNicholl, PharmD, BCPS, and Christine Jamjian, PharmD, University of California San Francisco. Updated October 2012.
transparent gif
transparent gifgrey bulletAntiretroviral Therapy-Associated Common and/or Severe Adverse Effects
Table 13, Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. March 27, 2012.
transparent gif
Drug Characteristics
transparent gifgrey bulletAntiretroviral Drug Profiles
Susa Coffey, MD, and Laurence Peiperl, MD. University of California San Francisco.
transparent gif
transparent gifgrey bulletCurrently Approved Drugs for HIV: A Comparative Chart
AIDSmeds.com. Table showing standard antiretroviral dosages, plus dosing and side effect considerations and links to in-depth drug monographs.
transparent gif
Drug Interactions
transparent gifgrey bullet ARV Interactions with HCV Serine Protease Inhibitors
Susa Coffey, MD, and Annie Luetkemeyer, MD, University of California San Francisco. Updated January 2013.
transparent gif
transparent gifgrey bullet Database of Antiretroviral Drug Interactions
HIV InSIte, Ian R. McNicholl, PharmD, BCPS, University of California San Francisco. Create custom reports with this interactive tool.
transparent gif
transparent gifgrey bullet Dosage Adjustments for ARV-ARV Drug Interactions
Susa Coffey, MD, and Ian R. McNicholl, PharmD, BCPS, University of California San Francisco. Updated October 2012.
transparent gif
transparent gifgrey bulletDrugs That Should Not Be Used with PIs, NNRTIs, or CCR5 Antagonists
Table 14, Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. March 27, 2012.
transparent gif
transparent gifgrey bulletEtravirine-ARV Interactions
Susa Coffey, MD, HIV InSite Medical Editor; Ian R. McNicholl, PharmD, HIV InSite Pharmacy Editor. Updated July 2011. Reference table to help clinicians navigate the complexities of drug interactions with this NNRTI.
transparent gif
transparent gifgrey bulletInteractions between ARVs and Statin Medications: Recommendations for Coadministration
Susa Coffey, MD, HIV InSite Medical Editor. Updated October 2012.
transparent gif
transparent gifgrey bullet Recreational Drugs and HIV Antivirals: A Guide to Interactions for Clinicians
Christine Kubin, PharmD, and Antonio Urbina, MD, New York/New Jersey AIDS Education and Training Center. 2008. Contains information on interactions with alcohol, street drugs, and erectile dysfunction agents.
transparent gif
Regimen Selection / Treatment Strategy
transparent gifgrey bullet Summary tables from the Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Panel on Antiretroviral Guidelines for Adult and Adolescents. U.S. Department of Health and Human Services. March 27, 2012.
transparent gif
grey bulletPreferred and Alternative Antiretroviral Regimens for Antiretroviral Therapy-Naive Patients (Table 5a)
transparent gif
grey bulletAcceptable Antiretroviral Regimens for Treatment-Naive Patients (Table 5b)
transparent gif
grey bulletAdvantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy (Table 6)
transparent gif
grey bulletARV Regimens or Components Not Recommended as Initial Therapy (Table 7)
transparent gif
grey bulletARV Regimens or Components That Should Not Be Offered at Any Time (Table 8)
transparent gif
Access Information
transparent gifgrey bulletFDA-Approved and Investigational Antiretrovirals
HIV InSite. Comprehensive chart of FDA-approved and experimental drugs.
transparent gif
transparent gifgrey bulletExpanded Access, Compassionate Use, and Treatment IND Programs
HIV InSite. Listing of programs that provide patients with limited access to promising experimental treatments before the medications have been given full approval by the U.S. Food and Drug Administration. November 2007.
transparent gif
transparent gifgrey bulletApproved and Tentatively Approved Antiretrovirals in Association with the President's Emergency Plan (PEPFAR)
U.S. Food and Drug Administration. Table detailing FDA approvals as part of a special initative for granting approval to manufacturers of generic antiretrovirals so that these drugs may be purchased for use outside the U.S. and paid for with PEPFAR funding.
transparent gif